Navigation Links
Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
Date:6/20/2013

Greensboro, NC (PRWEB) June 20, 2013

Last week the US Food and Drug Administration’s Center for Veterinary Medicine approved the first application of Piedmont Pharmaceuticals’ invention of a canine soft chew formulation containing a veterinary medicine. This flavored soft chew formulation contains carprofen and is labeled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category.

The soft chew formulation will provide pet owners with a convenient and friendly way to medicate dogs. According to Roland Johnson, Chairman and CEO of Piedmont Pharmaceuticals, “The veterinary pharmaceutical industry has been working on a soft chew formulation for the past two decades and we are proud, following a relatively short development timeline, to have successfully registered this highly palatable, wonderfully textured product to positively impact the medicating experience for both dogs and their owners.” In addition Johnson noted that, “this formulation has been issued multiple US patents in the past two years.”

Osteoarthritis is a problem for dogs as they get older, particularly for larger breeds. A common sign that owners will notice in their dog is difficulty climbing stairs or jumping into the back of a car. Pain is the third largest veterinary treatment category in companion animal health.

Piedmont Pharmaceuticals is a company that develops FDA and EPA regulated products for animals, emphasizing dogs and cats. In addition, their pipeline includes livestock products along with a group of technology-related human products.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10854864.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park
2. Piedmont Chemical Launches 100 Percent Renewable Polyester Polyols Leveraging Renewable Chemicals from DuPont Tate & Lyle Bio Products and Myriant Corporation
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):